Scapho 150mg (Secukinumab )
Scapho 150mg is used as prescription drug given by a doctor rheumatologist for adults with psoriatic arthritis and ankylosing spondylitis.
Secukinumab is a generic form of brand name scapho and scapho is a type of biological therapy which prevent the function of IL-17A proteins. This activity alters the immune activity and inflammation which cause the symptoms of psoriatic arthritis.
Scapho 150mg is used as prescription drug given by a doctor rheumatologist for adults with psoriatic arthritis and ankylosing spondylitis.
INDICATION
Scapho 150mg prescribed for the therapy of patients with following condition :
Plaque Psoriasis
Psoriatic arthritis
Ankylosing spondylitis
MECHANISM OF ACTION
Secukinumab consist of human IgG1 monoclonal antibody whichcarefullyconnects to the interleukin-17A (IL-17A) cytokine and prohibits its concomitant with the IL-17 receptor.
IL-17A is a naturally appearing cytokine included in normal inflammatory and immune responses. Secukinumab prevents the release of proinflammatory cytokines and chemokines.
ADME
Absorption: high plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days Distribution: volume of distribution is 7.1 – 8.6 in IV administration Metabolism: Intracellular catabolism is the drug metabolized Elimination: half-life is 22-31 days
DOSAGE MANAGEMENT
Plaque Psoriasis :
Initial dose for the patients is given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, given 300 mg SC once monthly
The prescribed dose for plaque psoriasis is 150 mg may be acceptable for some patients
Psoriatic Arthritis :
The recommended dosage for Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho the recommended dosewith loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scaphothe recommended dose without loading dose administrated 150 mg SC q4wk.
Dosage of 300 mgshould be taken by patient ifcontinues to have active psoriatic arthritis,
May be given with or without methotrexate.
Ankylosing Spondylitis :
The recommended dose is given with or without a loading dosage by SC injection
Scapho the recommended dose with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho the recommended dose without a loading dose is administrated150 mg SC q4wk
PRECAUTIONS
When using Scaphowill increased risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
• Do not take vaccination of Secukinumab recipients with live virus vaccines because of probability of transmission of infection by vaccine
• When using scapho medication then Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment
• The treatment with Secukinumab should not be given to patients with active tuberculosis infection.
SIDE EFFECTS
Swelling under your skin
• Sores on your genital or anal areas
• Painful skin sores
• infections
• Nasopharyngitis
• Diarrhea
• URT infection
• Rhinitis
• Oral herpes
• Pharyngitis
• Urticaria
• Rhinorrhoea
DRUG INTERACTION
CYP450 substrates co administration with scapho injection may altered by increased levels of certain cytokines
Live vaccinations co administration with scapho should be avoided
CONTRAINDICATIONS
Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients
PREGNANCY
Pregnancy category is B
Use the scapho 150mg with caution during pregnancy
LACTATION
Excretion into human milk is unknown. Use with caution while administrating scapho to a nursing woman
STORAGE
Store the drug at 20°C – 80°C
Store in original carton and protect from light until the time of use
MISSED DOSE
If failed to take a dose, patients should consult with medical practitioner and follow the instructions given by them.
Brand name | Scapho |
Active substance | Секукинумаб |
Packaging | 1 флакон |
Product form | Инъекция |
There are no comments yet